Neurizon Therapeutics Ltd
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neur… Read more
Neurizon Therapeutics Ltd (NUZ) - Total Assets
Latest total assets as of June 2025: AU$4.36 Million AUD
Based on the latest financial reports, Neurizon Therapeutics Ltd (NUZ) holds total assets worth AU$4.36 Million AUD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Neurizon Therapeutics Ltd - Total Assets Trend (2001–2025)
This chart illustrates how Neurizon Therapeutics Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Neurizon Therapeutics Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Neurizon Therapeutics Ltd's total assets of AU$4.36 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 95.5% |
| Accounts Receivable | AU$0.00 | 0.0% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$1.50K | 0.0% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2001–2025)
This chart illustrates how Neurizon Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neurizon Therapeutics Ltd's current assets represent 100.0% of total assets in 2025, an increase from 47.7% in 2001.
- Cash Position: Cash and equivalents constituted 95.5% of total assets in 2025, up from 38.3% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 40.0% in 2001.
- Asset Diversification: The largest asset category is property, plant & equipment at 0.0% of total assets.
Neurizon Therapeutics Ltd Competitors by Total Assets
Key competitors of Neurizon Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Neurizon Therapeutics Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Neurizon Therapeutics Ltd generates 0.46x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Neurizon Therapeutics Ltd is currently not profitable relative to its asset base.
Neurizon Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.84 | 12.42 | 4.12 |
| Quick Ratio | 2.84 | 12.42 | 3.31 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$2.82 Million | AU$ 10.23 Million | AU$ 3.30 Million |
Neurizon Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Neurizon Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 24.41 |
| Latest Market Cap to Assets Ratio | 4.25 |
| Asset Growth Rate (YoY) | -60.8% |
| Total Assets | AU$4.36 Million |
| Market Capitalization | $18.51 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Neurizon Therapeutics Ltd's assets at a significant premium ( 4.25x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Neurizon Therapeutics Ltd's assets decreased by 60.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Neurizon Therapeutics Ltd (2001–2025)
The table below shows the annual total assets of Neurizon Therapeutics Ltd from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$4.36 Million | -60.82% |
| 2024-06-30 | AU$11.12 Million | +81.47% |
| 2023-06-30 | AU$6.13 Million | 0.00% |
| 2022-06-30 | AU$6.13 Million | -39.17% |
| 2021-06-30 | AU$10.08 Million | -7.99% |
| 2020-06-30 | AU$10.95 Million | +1.93% |
| 2019-06-30 | AU$10.75 Million | +25.02% |
| 2018-06-30 | AU$8.60 Million | +2.84% |
| 2017-06-30 | AU$8.36 Million | +1.99% |
| 2016-06-30 | AU$8.20 Million | +30.97% |
| 2015-06-30 | AU$6.26 Million | -34.29% |
| 2014-06-30 | AU$9.52 Million | +15.99% |
| 2013-06-30 | AU$8.21 Million | +240.84% |
| 2012-06-30 | AU$2.41 Million | +66.02% |
| 2011-06-30 | AU$1.45 Million | 0.00% |
| 2010-06-30 | AU$1.45 Million | -78.75% |
| 2009-06-30 | AU$6.83 Million | -9.81% |
| 2008-06-30 | AU$7.57 Million | -5.28% |
| 2007-06-30 | AU$7.99 Million | -12.84% |
| 2006-06-30 | AU$9.17 Million | 0.00% |
| 2005-06-30 | AU$9.17 Million | +73.84% |
| 2004-06-30 | AU$5.27 Million | +482.91% |
| 2003-06-30 | AU$904.88K | -81.63% |
| 2002-06-30 | AU$4.93 Million | -1.29% |
| 2001-06-30 | AU$4.99 Million | -- |